Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells

Yu,Ziyi; Lou,Longquan; Zhao,Yi

doi:10.3892/or.2018.6482

Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells

Authors:
- Ziyi Yu
- Longquan Lou
- Yi Zhao
View Affiliations

Affiliations: Jiangsu Breast Disease Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China
Published online on: June 7, 2018 https://doi.org/10.3892/or.2018.6482
Pages: 704-714
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor 18 (FGF18) increases cell motility and invasion in colon tumors, and is linked with ovarian and lung tumors. Furthermore, the increased expression of FGF18 mRNA and protein has been associated with poor overall survival in cancer patients. However, its function has not been investigated in breast cancer. In the present study, we demonstrated that FGF18 promoted cell growth and metastasis in vitro and stimulated tumor growth in xenograft models in vivo. FGF18 mediated the proliferation of MDA‑MB‑231 cells via the ERK/c‑Myc signaling pathway and induced epithelial‑to‑mesenchymal transition (EMT) factors to promote cancer migration and invasion. The decreased expression of FGF18 was strongly correlated with the loss/reduction of p‑ERK, c‑Myc, N‑cadherin, vimentin and Snail 1 protein in MDA‑MB‑231 cells. Collectively, our results indicated that FGF18 played an important role in the growth and metastasis of breast cancer via the ERK/c‑Myc signaling pathway and EMT, indicating that FGF18 may be a potential molecular treatment target for breast cancer.

View Figures

View References

1	Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, et al: Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 67:194–232. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 352:930–942. 1998.
4	Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, Stoldt V, Gressner AM and Kiefer P: Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors. 23:87–95. 2005. View Article : Google Scholar : PubMed/NCBI
5	Diez Del Corral R and Morales AV: The Multiple roles of FGF signaling in the developing spinal cord. Front Cell Dev Biol. 5:582017. View Article : Google Scholar : PubMed/NCBI
6	Majidinia M, Sadeghpour A and Yousefi B: The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 233:2937–2948. 2018. View Article : Google Scholar : PubMed/NCBI
7	Presta M, Chiodelli P, Giacomini A, Rusnati M and Ronca R: Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 179:171–187. 2017. View Article : Google Scholar : PubMed/NCBI
8	Itoh N and Ornitz DM: Evolution of the Fgf and Fgfr gene families. Trends Genet. 20:563–569. 2004. View Article : Google Scholar : PubMed/NCBI
9	Elo T, Lindfors PH, Lan Q, Voutilainen M, Trela E, Ohlsson C, Huh SH, Ornitz DM, Poutanen M, Howard BA, et al: Ectodysplasin target gene Fgf20 regulates mammary bud growth and ductal invasion and branching during puberty. Sci Rep. 7:50492017. View Article : Google Scholar : PubMed/NCBI
10	Feng S, Wang J, Zhang Y, Creighton CJ and Ittmann M: FGF23 promotes prostate cancer progression. Oncotarget. 6:17291–17301. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY, et al: Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet. 85:53–63. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N and Takada S: FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 16:870–879. 2002. View Article : Google Scholar : PubMed/NCBI
13	Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, Grasl-Kraupp B, Holzmann K, Berger W, Wrba F, et al: FGF18 in colorectal tumour cells: Autocrine and paracrine effects. Carcinogenesis. 29:15–24. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G and Birrer MJ: FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 123:4435–4448. 2013. View Article : Google Scholar : PubMed/NCBI
15	Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM and Nakamura Y: Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res. 63:6116–6120. 2003.PubMed/NCBI
16	MacCorkle RA and Tan TH: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys. 43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
17	Martin GS: Cell signaling and cancer. Cancer Cell. 4:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
19	Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN and Cleveland JL: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16:2530–2543. 2002. View Article : Google Scholar : PubMed/NCBI
20	Liao DJ and Dickson RB: c-Myc in breast cancer. Endocr Relat Cancer. 7:143–164. 2000. View Article : Google Scholar : PubMed/NCBI
21	Neelakantan D, Zhou H, Oliphant MU, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et al: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 8:157732017. View Article : Google Scholar : PubMed/NCBI
22	Hazan RB, Phillips GR, Qiao RF, Norton L and Aaronson SA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
23	Maeda M, Johnson KR and Wheelock MJ: Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI
24	Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
25	Canesin G, Cuevas EP, Santos V, López-Menéndez C, Moreno-Bueno G, Huang Y, Csiszar K, Portillo F, Peinado H, Lyden D and Cano A: Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: Novel partners in E-cadherin repression and early metastasis colonization. Oncogene. 34:951–964. 2015. View Article : Google Scholar : PubMed/NCBI
26	Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT and Odero-Marah VA: Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer. 12:3362012. View Article : Google Scholar : PubMed/NCBI
27	Blanckaert VD, Hebbar M, Louchez MM, Vilain MO, Schelling ME and Peyrat JP: Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res. 4:2939–2947. 1998.PubMed/NCBI
28	Cai Y, Zhang J, Lao X, Jiang H, Yu Y, Deng Y, Zhong J, Liang Y, Xiong L and Deng N: Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer. Cancer Sci. 107:1141–1150. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chen T, Gong W, Tian H, Wang H, Chu S, Ma J, Yang H, Cheng J, Liu M, Li X and Jiang C: Fibroblast growth factor 18 promotes proliferation and migration of H460 cells via the ERK and p38 signaling pathways. Oncol Rep. 37:1235–1242. 2017. View Article : Google Scholar : PubMed/NCBI
30	Koneczny I, Schulenburg A, Hudec X, Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P and Marian B: Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Mol Carcinog. 54:789–799. 2015. View Article : Google Scholar : PubMed/NCBI
31	Yang XL, Liu KY, Lin FJ, Shi HM and Ou ZL: CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol Rep. 38:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
32	Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, et al: RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 21:1038–1047. 2015. View Article : Google Scholar : PubMed/NCBI
33	Urosevic J, Garcia-Albéniz X, Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, et al: Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 16:685–694. 2014. View Article : Google Scholar : PubMed/NCBI
34	Whyte J, Bergin O, Bianchi A, McNally S and Martin F: Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 11:2092009.
35	Wilde BR and Ayer DE: Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br J Cancer. 113:1529–1533. 2015. View Article : Google Scholar : PubMed/NCBI
36	Fallah Y, Brundage J, Allegakoen P and Shajahan-Haq AN: MYC-driven pathways in breast cancer subtypes. Biomolecules. 7:E532017. View Article : Google Scholar : PubMed/NCBI
37	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
38	Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004. View Article : Google Scholar : PubMed/NCBI
39	Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation, apoptosis and epithelial mesenchymal transition by targeting PMEL through the Wnt signaling pathway. Biosci Rep. 37:BSR20170743. 2017. View Article : Google Scholar
40	Derynck R, Muthusamy BP and Saeteurn KY: Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 31:56–66. 2014. View Article : Google Scholar : PubMed/NCBI
41	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI